Insys Therapeutics (NASDAQ: INSY) reported Q1 EPS of $0.11, $0.04 better than the analyst estimate of $0.07. Revenue for the quarter came in at $62 million versus the consensus estimate of $61.31 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.